Abstract:Summary In this Review, we examine the concurrent outbreaks of mpox in Africa, focusing on clade 1a, the newly emerged clade 1b, and clade 2b lineage A, and how they differ from the 2022 global outbreak caused by clade 2b lineage B.1. Historically, clades 1a and 2a have caused sporadic, small outbreaks in central and west Africa, respectively, primarily through zoonotic transmission. Clade 2b first caused an outbreak in Nigeria in 2017, and later spread globally via sexual contact in 2022. In August, 2024, WHO declared a global health emergency due to the newly identified clade 1b outbreak in eastern Democratic Republic of the Congo. This outbreak has now expanded to several other countries and is spreading through direct and sexual contact in urban centres and refugee camps. Clades, route of exposure, infectious dose, and host immune response are the main factors influencing clinical presentation of mpox. For clades 1a and 2a, zoonotic transmission plays an important role, whereas for clades 1b and 2b, the spread occurs through sustained human-to-human transmission without zoonotic exposure. For both clades 1a and 2a, lesions have a generalised centrifugal distribution, whereas for clade 2b they are mainly localised to the anogenital area. For clade 1b, data are still emerging, but current cases show a mix of localised lesions and centrifugal distribution. The severity of the disease is higher for clade 1a (case fatality rate up to 12%) compared with other clades (case fatality rates 0–3·6%). Diagnostic challenges include false negative results for clade 1b with existing PCR assays and poor testing access in remote areas. Tecovirimat, the primary antiviral during the 2022 outbreak, has shown reduced effectiveness against clade 1a in preliminary study results, whereas its efficacy against other clades is still under investigation. The modified vaccinia Ankara–Bavarian Nordic vaccine has been shown to be up to 90% effective against clade 2b after two doses and is safe for children, although its effectiveness drops to 20% when used as post-exposure prophylaxis. Given the evolving nature of the monkeypox virus, ongoing research and strong public health responses are key to managing potential future outbreaks.

Mpox is accelerating antimicrobial resistance in Africa, officials warn

Mpox continues to spread in Africa and threatens global health security

Mpox in East Africa: Learning from COVID-19 and Ebola to Strengthen Public Health Responses

Mpox needs a locally tailored global response

Africa aims to avert an mpox pandemic

The 2024 Public Health Emergency of International Concern: A Global Failure to Control Mpox

Democratic Republic of the Congo: a strengthened response to mpox could help revitalise the country's healthcare system

A critical review of mpox outbreaks, risk factors, and prevention efforts in Africa: lessons learned and evolving practices

Mpox is a public health emergency — what happens now?

Public health response to Mpox: Safeguarding vulnerable Key Populations and People Living with HIV in Zanzibar

First mpox vaccines arrive in Africa as officials work "blindly" to contain outbreaks

The rising mpox crisis

Mpox Resurgence: A Multifaceted Analysis for Global Preparedness

Mpox in Children and Adolescents during Multicountry Outbreak, 2022-2023

Mpox: The alarm went off. Have we gone back to sleep?

Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes

Concurrent outbreaks of mpox in Africa—an update

The Fragmented Picture of Antimicrobial Resistance in Kenya: A Situational Analysis of Antimicrobial Consumption and the Imperative for Antimicrobial Stewardship

Mpox, sexually transmitted infections and combination prevention: insights from a major cohort in Rio de Janeiro, Brazil

Mpox: an old disease poses a new threat

Why is mpox a global emergency again so soon?